Safety Study of Albuterol Spiromax® in Subjects With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Albuterol MDPI
Drug: Placebo MDPI

Registration Number: NCT01698320

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Brief Summary: The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance through the life of the device during the study.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 364

Inclusion Criteria

Written informed consent and HIPAA signed and dated by the subject or written informed assent signed and dated both by the subject and/or parent/caregiver/legal guardian before conducting any study related procedure.
Males or females with asthma ages 12 years or older at screening.
Documented history of persistent asthma and current use of an MDI containing any short-acting beta-adrenergic agonist (e.g. albuterol, levalbuterol,) on average of at least once/week over the 4-weeks prior to screening. The asthma diagnosis must be consistent with the diagnosis of asthma as per the National Asthma Education and Prevention Program.
If female, is currently not pregnant, breast feeding, or attempting to become pregnant (for 4 weeks before the screening visit and throughout the duration of the study), and is of Non-childbearing potential, defined as:
- ≥1 year post-menopausal or
- Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or hysterectomy) or is of
- Childbearing potential, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control
General good health in the opinion of the investigator as indicated by medical history, physical examination, laboratory tests (hematology, serum chemistry and urinalysis) assessed as either normal or abnormal not clinically significant (NCS) per the principal investigator, as well as a 12-lead ECG interpreted as either "Normal" or "Abnormal NCS" as determined by the central cardiologist. Subjects must also be free of any clinically significant, uncontrolled concomitant conditions other than asthma that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the trial.
Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, and being compliant with all study requirements (visits, record-keeping, etc).
Non-smoker for at least one year prior to the screening visit and a maximum pack-year (PY) smoking history of 10 years.
Able to demonstrate proper inhaler technique with study inhaler.

Exclusion Criteria

Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit.
Participation in any investigational drug trial within 30 days preceding the screening visit or planned participation in another investigational drug trial at any time during this trial.
A known hypersensitivity to albuterol or any of the excipients in the formulations.
History of severe milk protein allergy
History of an upper or lower respiratory tract infection or disorder (including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza, etc) which is not resolved at least 1 week prior to the SV.
History of alcohol or drug abuse within two years preceding the SV.
Use of any protocol prohibited concomitant medications for asthma (any oral β2-adrenergic agonists) or any protocol prohibited concomitant non-asthma medications including treatment with β2-adrenergic receptor antagonists and non-selective β-receptor blocking agents such as β-blocking anti-hypertensive products (administered by any route), MAO inhibitors, and/or tricyclic antidepressants. (Subject's own MDI short-acting β-agonist rescue inhaler should be used until the start of the Run-In period when a study rescue inhaler is provided.)
Inability or unwillingness to comply with the protocol requirements.
History of life-threatening asthma [defined here as an asthma episode requiring intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures.]
Any asthma exacerbation within 3 months of the SV requiring oral or systemic corticosteroids or any hospitalization for asthma within 6 months of the SV.

Note: An exacerbation of asthma is defined as any worsening of asthma requiring any treatment other than rescue albuterol or the subject's regular asthma maintenance therapy. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization or a change in subject's regular asthma maintenance treatment. A subject does not need to be withdrawn from the study due to an asthma exacerbation unless hospitalization is required or unless the principal investigator believes it is in the subjects' best interest to withdraw from the study.

Previous participation in an inhaled Albuterol Spiromax® (Teva) study, with the exception of the ABS-AS-306 study.
Study participation by clinical investigator site employees and/or their immediate relatives.
Study participation by related or non-related individuals living in the same household, i.e. only one subject per household may participate in the study.
Any clinically significant endocrine, hematological, hepatic, renal, gastrointestinal, neurological, cardiac, metabolic, immunological, any non-asthmatic acute or chronic pulmonary condition (including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis, cystic fibrosis), and malignancy other than basal cell carcinoma. Significant is defined for this protocol as any condition that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the safety analyses.
Any medical or psychological condition that in the investigator's opinion should preclude enrollment.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Albuterol MDPI-Albuterol MDPI	Albuterol MDPI	During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day. The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise.
Placebo MDPI-Albuterol MDPI	Placebo MDPI	During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime. The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise.
Placebo MDPI-Albuterol MDPI	Albuterol MDPI	During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime. The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Pulse Measurements to Week 12 and Week 52	Week 0, Week 12 and Week 52	Participants were seated at least 2 minutes before pulse measurements were obtained by radial pulse. Week 12 values represent change from Week 0. Week 52 values represent change from Week 12.
Participants With Abnormal and Clinically Relevant Physical Exam Findings at Weeks 0, 12 and 52	Weeks 0, 12 and 52	The physical exam was performed by a qualified healthcare professional, and when possible, the same qualified healthcare professional that performed the physical examination at study screening performed all the scheduled physical examinations. Abnormalities and clinical relevance were determined by the qualified healthcare professional. HEENT = head, eyes, ears, nose, throat
Change From Baseline in Blood Pressure Measurements to Week 12 and Week 52	Week 0, Week 12 and Week 52	Participants were seated at least 2 minutes before blood pressure measurements were obtained by either an electronic or manual sphygmomanometer. Week 12 values represent change from Week 0. Week 52 values represent change from Week 12.
Participants With Adverse Experiences During Weeks 13-52 (Open-Label Period)	Weeks 13-52	Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Electrocardiogram (ECG) Results At Weeks 0, 12, and 52	Weeks 0 (screening visit), 12, and 52	A standard 12-lead ECG was performed at screening, week 12, and week 52 or early termination/discontinuation. The ECG recording methods were centralized and standardized across all study participants. A centralized cardiologist was responsible for providing all ECG interpretations.
Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period)	Day 1 to Week 12	Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (30): Teva Investigational Site 10146
🇺🇸
Bellevue, Nebraska, United States
Teva Investigational Site 10154
🇺🇸
Gainesville, Georgia, United States
Teva Investigational Site 10143
🇺🇸
Cincinnati, Ohio, United States
Teva Investigational Site 10155
🇺🇸
El Paso, Texas, United States
Teva Investigational Site 10147
🇺🇸
Canton, Ohio, United States
Teva Investigational Site 10168
🇺🇸
Miami, Florida, United States
Teva Investigational Site 10150
🇺🇸
Eugene, Oregon, United States
Teva Investigational Site 10149
🇺🇸
New Braunfels, Texas, United States
Teva Investigational Site 10153
🇺🇸
Raleigh, North Carolina, United States
Teva Investigational Site 10165
🇺🇸
Seattle, Washington, United States
Teva Investigational Site 10166
🇺🇸
Wheaton, Maryland, United States
Teva Investigational Site 10142
🇺🇸
Plymouth, Minnesota, United States
Teva Investigational Site 10167
🇺🇸
Sylvania, Ohio, United States
Teva Investigational Site 10162
🇺🇸
Bethesda, Maryland, United States
Teva Investigational Site 10170
🇺🇸
San Antonio, Texas, United States
Teva Investigational Site 10161
🇺🇸
Louisville, Kentucky, United States
Teva Investigational Site 10151
🇺🇸
Minneapolis, Minnesota, United States
Teva Investigational Site 10163
🇺🇸
Burke, Virginia, United States
Teva Investigational Site 10157
🇺🇸
San Diego, California, United States
Teva Investigational Site 10159
🇺🇸
Denver, Colorado, United States
Teva Investigational Site 10148
🇺🇸
Denver, Colorado, United States
Teva Investigational Site 10169
🇺🇸
Huntington Beach, California, United States
Teva Investigational Site 10152
🇺🇸
St. Louis, Missouri, United States
Teva Investigational Site 10160
🇺🇸
Skillman, New Jersey, United States
Teva Investigational Site 10141
🇺🇸
High Point, North Carolina, United States
Teva Investigational Site 10158
🇺🇸
Miami, Florida, United States
Teva Investigational Site 10144
🇺🇸
Rochester, New York, United States
Teva Investigational Site 10156
🇺🇸
Portland, Oregon, United States
Teva Investigational Site 10145
🇺🇸
San Antonio, Texas, United States
Teva Investigational Site 10164
🇺🇸
Greenfield, Wisconsin, United States